UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $236,000 Stock Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC cut its holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) by 45.6% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 23,034 shares of the company’s stock after selling 19,286 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in ORIC Pharmaceuticals were worth $236,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in ORIC. First Turn Management LLC grew its position in ORIC Pharmaceuticals by 38.1% in the second quarter. First Turn Management LLC now owns 1,515,960 shares of the company’s stock valued at $10,718,000 after purchasing an additional 418,389 shares in the last quarter. Millennium Management LLC boosted its stake in shares of ORIC Pharmaceuticals by 297.4% during the 2nd quarter. Millennium Management LLC now owns 782,299 shares of the company’s stock worth $5,531,000 after buying an additional 585,447 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of ORIC Pharmaceuticals by 190.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 466,662 shares of the company’s stock valued at $3,299,000 after acquiring an additional 305,860 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of ORIC Pharmaceuticals by 152.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 410,229 shares of the company’s stock valued at $4,205,000 after acquiring an additional 247,863 shares during the last quarter. Finally, Monaco Asset Management SAM boosted its position in ORIC Pharmaceuticals by 132.0% during the second quarter. Monaco Asset Management SAM now owns 301,650 shares of the company’s stock valued at $2,133,000 after purchasing an additional 171,650 shares during the last quarter. Institutional investors own 95.05% of the company’s stock.

Insider Buying and Selling

In related news, CEO Jacob Chacko sold 24,660 shares of the company’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $8.28, for a total transaction of $204,184.80. Following the completion of the transaction, the chief executive officer now directly owns 778,648 shares in the company, valued at $6,447,205.44. This represents a 3.07 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Dominic Piscitelli sold 8,851 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $8.28, for a total transaction of $73,286.28. Following the completion of the sale, the chief financial officer now owns 106,764 shares in the company, valued at $884,005.92. This represents a 7.66 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 42,361 shares of company stock valued at $350,749 over the last 90 days. 5.55% of the stock is owned by corporate insiders.

ORIC Pharmaceuticals Stock Performance

NASDAQ ORIC opened at $8.21 on Friday. The stock has a market cap of $579.36 million, a PE ratio of -4.56 and a beta of 1.13. ORIC Pharmaceuticals, Inc. has a 52-week low of $6.33 and a 52-week high of $16.65. The firm has a 50-day moving average of $9.24 and a 200-day moving average of $9.34.

ORIC Pharmaceuticals (NASDAQ:ORIC) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.01). As a group, analysts predict that ORIC Pharmaceuticals, Inc. will post -1.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ORIC has been the topic of several recent analyst reports. Wedbush reaffirmed an “outperform” rating and set a $20.00 price target on shares of ORIC Pharmaceuticals in a research report on Tuesday, November 12th. Wells Fargo & Company began coverage on shares of ORIC Pharmaceuticals in a report on Thursday, October 31st. They set an “overweight” rating and a $20.00 target price on the stock. Stifel Nicolaus assumed coverage on shares of ORIC Pharmaceuticals in a research note on Friday, September 6th. They issued a “buy” rating and a $20.00 price target for the company. HC Wainwright restated a “buy” rating and set a $21.00 price objective on shares of ORIC Pharmaceuticals in a research note on Monday, November 4th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ORIC Pharmaceuticals in a report on Monday, September 23rd. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, ORIC Pharmaceuticals has an average rating of “Buy” and a consensus target price of $18.29.

ORIC Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.